Glimisave Max 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 750mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The combination of these two agents provides complementary mechanisms of action, resulting in effective blood glucose regulation in patients inadequately controlled by diet and exercise alone. Glimisave Max 1 Tablet PR is particularly beneficial for patients who require dual therapy to achieve target glycemic levels. It is recommended to be administered orally with meals to minimize gastrointestinal side effects commonly associated with Metformin. Regular monitoring of blood glucose levels and renal function is advised during therapy to ensure safety and efficacy. Caution is warranted in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoglycemia. This formulation offers a convenient once-daily dosing regimen, enhancing patient compliance and optimizing therapeutic outcomes in type 2 diabetes management.

Dosage & How to Use